$INSP
Inspire Medical Systems, Inc. Stock $insp

$insp Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000160955021000010 Filed on February 24, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$46.01M	$26.91M	$20.86M
YoY Change	71.0%	62.49%	59.81%
Cost Of Revenue	$7.160M	$4.240M	$3.456M
YoY Change	68.87%	32.92%	40.09%
Gross Profit	$38.85M	$22.67M	$17.41M
YoY Change	71.39%	69.59%	64.41%
Gross Profit Margin	84.44%	84.25%	83.43%
Selling, General & Admin	$38.63M	$28.19M	$22.43M
YoY Change	37.03%	74.98%	-9.47%
% of Gross Profit	99.44%	124.37%	128.86%
Research & Development	$7.290M	$3.770M	$3.623M
YoY Change	93.37%	75.35%	104.57%
% of Gross Profit	18.77%	16.63%	20.81%
Depreciation & Amortization	$250.0K	$160.0K	$130.0K
YoY Change	56.25%	60.0%	30.0%
% of Gross Profit	0.64%	0.71%	0.75%
Operating Expenses	$45.91M	$31.96M	$26.06M
YoY Change	43.65%	74.93%	71.02%
Operating Profit	-$7.062M	-$9.293M	-$8.651M
YoY Change	-24.01%	89.5%	86.08%
Interest Expense	-$460.0K	$250.0K	$529.0K
YoY Change	-284.0%	92.31%	-22.21%
% of Operating Profit
Other Income/Expense, Net	$60.00K	$10.00K	$404.0K
YoY Change	500.0%	-200.0%	-1018.18%
Pretax Income	-$7.460M	-$9.040M	-$8.247M
YoY Change	-17.48%	89.12%	75.73%
Income Tax	$30.00K	$40.00K	$0.00
% Of Pretax Income
Net Earnings	-$7.484M	-$9.080M	-$8.247M
YoY Change	-17.58%	90.04%	75.73%
Net Earnings / Revenue	-16.27%	-33.75%	-39.53%
Basic Earnings Per Share
Diluted Earnings Per Share	-$277.1K	-$377.1K	-$344.6K
COMMON SHARES
Basic Shares Outstanding	26.94M shares	24.06M shares	23.91M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$234.4M	$149.5M	$151.6M
YoY Change	56.79%	-20.56%	25.91%
Cash & Equivalents	$190.5M	$22.86M	$48.04M
Short-Term Investments	$43.80M	$126.6M	$103.6M
Other Short-Term Assets	$2.000M	$2.200M	$3.200M
YoY Change	-9.09%	29.41%	220.0%
Inventory	$8.479M	$5.834M	$4.675M
Prepaid Expenses	$1.965M	$2.206M	$3.200M
Receivables	$25.06M	$13.13M	$10.99M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$269.9M	$170.6M	$170.5M
YoY Change	58.15%	-14.37%	31.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.311M	$3.045M	$2.757M
YoY Change	74.42%	279.68%	260.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$6.300M	$9.600M
YoY Change	-100.0%
Other Assets	$204.0K	$381.0K	$400.0K
YoY Change	-46.46%
Total Long-Term Assets	$11.32M	$10.62M	$12.76M
YoY Change	6.62%	1223.82%	1568.37%
TOTAL ASSETS
Total Short-Term Assets	$269.9M	$170.6M	$170.5M
Total Long-Term Assets	$11.32M	$10.62M	$12.76M
Total Assets	$281.2M	$181.3M	$183.2M
YoY Change	55.14%	-9.41%	40.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.200M	$4.500M	$4.800M
YoY Change	60.0%	32.35%	100.0%
Accrued Expenses	$13.52M	$12.40M	$7.865M
YoY Change	9.03%	60.46%	58.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.73M	$16.86M	$12.70M
YoY Change	22.95%	51.11%	67.25%
LONG-TERM LIABILITIES
Long-Term Debt	$24.70M	$24.50M	$24.50M
YoY Change	0.82%	-1.61%	-1.21%
Other Long-Term Liabilities	$85.00K	$40.00K
YoY Change	112.5%
Total Long-Term Liabilities	$30.72M	$24.56M	$24.50M
YoY Change	25.06%	-1.46%	-1.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.73M	$16.86M	$12.70M
Total Long-Term Liabilities	$30.72M	$24.56M	$24.50M
Total Liabilities	$51.44M	$41.42M	$37.17M
YoY Change	24.2%	14.79%	14.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$237.3M	-$180.2M	-$171.1M
YoY Change	31.75%	22.63%	20.36%
Common Stock	$27.00K	$24.00K	$24.00K
YoY Change	12.5%	4.35%	14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.7M	$139.8M	$146.1M
YoY Change
Total Liabilities & Shareholders Equity	$281.2M	$181.3M	$183.2M
YoY Change	55.14%	-9.41%	40.17%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$7.484M	-$9.080M	-$8.247M
YoY Change	-17.58%	90.04%	75.73%
Depreciation, Depletion And Amortization	$250.0K	$160.0K	$130.0K
YoY Change	56.25%	60.0%	30.0%
Cash From Operating Activities	-$4.110M	-$6.080M	-$2.940M
YoY Change	-32.4%	135.66%	-17.42%
INVESTING ACTIVITIES
Capital Expenditures	-$610.0K	-$440.0K	-$1.070M
YoY Change	38.64%	131.58%
Acquisitions
YoY Change
Other Investing Activities	$12.00M	-$19.55M	$560.0K
YoY Change	-161.38%	-613.12%	-100.61%
Cash From Investing Activities	$11.40M	-$19.99M	-$500.0K
YoY Change	-157.03%	-652.21%	-99.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.530M	890.0K	190.0K
YoY Change	408.99%	-98.73%	375.0%
NET CHANGE
Cash From Operating Activities	-4.110M	-6.080M	-2.940M
Cash From Investing Activities	11.40M	-19.99M	-500.0K
Cash From Financing Activities	4.530M	890.0K	190.0K
Net Change In Cash	11.82M	-25.18M	-3.250M
YoY Change	-146.94%	-135.49%	-96.6%
FREE CASH FLOW
Cash From Operating Activities	-$4.110M	-$6.080M	-$2.940M
Capital Expenditures	-$610.0K	-$440.0K	-$1.070M
Free Cash Flow	-$3.500M	-$5.640M	-$1.870M
YoY Change	-37.94%	135.98%	-47.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13643000	USD
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001609550
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
CY2018Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1504
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	29000	USD
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38468
CY2020	dei	Entity Registrant Name EntityRegistrantName	Inspire Medical Systems, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1377674
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	5500 Wayzata Blvd.
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Golden Valley
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55416
CY2020	dei	City Area Code CityAreaCode	844
CY2020	dei	Local Phone Number LocalPhoneNumber	672-4357
CY2020	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2020	dei	Trading Symbol TradingSymbol	INSP
CY2020	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	2229464061	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27128567	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190518000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22860000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	43844000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	126605000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	42000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	48000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25063000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13131000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8479000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5834000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1965000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2206000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	269869000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	170636000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	6276000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5311000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3045000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5805000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	915000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	204000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	381000	USD
CY2020Q4	us-gaap	Assets Assets	281189000	USD
CY2019Q4	us-gaap	Assets Assets	181253000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7209000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4459000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13516000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12397000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20725000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16856000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	24746000	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	24522000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5886000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	85000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	30717000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	24562000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	51442000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	41418000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27069276	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27069276	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24107350	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24107350	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	467038000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	319865000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	29000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	102000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237347000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180156000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	229747000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	139835000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	281189000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	181253000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115381000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82050000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50593000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17623000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	90465000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53527000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	153966000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10056000	USD
CY2020	us-gaap	Gross Profit GrossProfit	97758000	USD
CY2019	us-gaap	Gross Profit GrossProfit	68407000	USD
CY2018	us-gaap	Gross Profit GrossProfit	40537000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26092000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12839000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7388000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	127874000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	103304000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	60915000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-56208000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-34897000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-20378000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2117000	USD
CY2019	us-gaap	Interest Expense InterestExpense	2119000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1092000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	3801000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	1870000	USD
CY2018	us-gaap	Interest Expense InterestExpense	3304000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	145000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-880000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1694000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1450000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57088000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33203000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21828000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	115000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-57203000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33243000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21828000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-73000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	154000	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-52000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57276000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33089000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21880000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.19
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.40
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.50
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26073418	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23804452	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14579662	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	1327000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	558000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	95000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2018	insp	Stock Issued During Period Value Conversion Of Warrants StockIssuedDuringPeriodValueConversionOfWarrants	855000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1219000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-52000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21828000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	163999000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1140000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	233000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1355000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6197000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	154000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33243000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	139835000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7050000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	294000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2361000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12817000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-73000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-57203000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	229747000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-57203000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33243000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21828000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	840000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	495000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	393000	USD
CY2020	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	22000	USD
CY2019	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	983000	USD
CY2018	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	648000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	224000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	268000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	568000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	972000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	904000	USD
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	12817000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6197000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	1219000	USD
CY2020	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	294000	USD
CY2019	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	233000	USD
CY2018	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	95000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2019	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2018	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-595000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	89000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	143000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-51000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	11842000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6480000	USD
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2836000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2645000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3167000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1003000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-416000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	905000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1326000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2048000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1034000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	439000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1145000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2944000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3581000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53045000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32846000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18694000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2455000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2739000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	250000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	52721000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	178074000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	115481000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	141803000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	137254000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	32342000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	86627000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43559000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83389000	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2018	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8000000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	531000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7050000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1140000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	558000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124654000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	181825000	USD
CY2020	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	2361000	USD
CY2019	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	1355000	USD
CY2018	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134065000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1964000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	190383000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	11000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	13000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	33000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	167658000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-74428000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	88333000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22860000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97288000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8955000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190518000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22860000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97288000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1893000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2033000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2019000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	816000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	103000	USD
CY2018Q2	insp	Reclassification Of Warrant Liability To Additional Paid In Capital ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital	900000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. We use significant judgment when making estimates related to the allowance for credit losses, inventory reserves, warranty reserves, the valuations of our common stock prior to our IPO, and stock-based awards. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	100000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
CY2020Q4	insp	Investments Allowance For Credit Loss InvestmentsAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of December 31, 2020 and 2019, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	892000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	781000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7587000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5053000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8479000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5834000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7156000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4050000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1845000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1005000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5311000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3045000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2020Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1100000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	11965000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10304000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	828000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1391000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1105000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13516000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12397000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Advertising Expense AdvertisingExpense	26400000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	18000000.0	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	9300000	USD
CY2020Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	72700000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	600000	USD
CY2020Q4	insp	Operating Leases Future Minimum Payments Net Present Value OperatingLeasesFutureMinimumPaymentsNetPresentValue	7400000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5805000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	915000	USD
CY2020Q4	insp	Operating Lease Liability Gross OperatingLeaseLiabilityGross	0	USD
CY2019Q4	insp	Operating Lease Liability Gross OperatingLeaseLiabilityGross	828000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5886000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5886000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	828000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	45000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1035000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1021000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	72000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	29000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1107000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1050000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	17000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	633000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	1172000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	1207000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	1242000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	3152000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7423000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1537000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5886000	USD
CY2020Q4	insp	Operating Lease Remaining Lease Discount Rate Percent OperatingLeaseRemainingLeaseDiscountRatePercent	0.052
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	USD
CY2020	insp	Operating Lease Remaining Lease Term OperatingLeaseRemainingLeaseTerm	P7Y4M24D
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9188000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	12250000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3062000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	24500000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	insp	Reclassification Of Warrant Liability To Additional Paid In Capital ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital	900000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2071616	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.47
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1014556	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	31.91
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	301058	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.86
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	7353000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	39958	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.64
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2745156	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.64
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	81453000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	809454	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	67.43
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	664617	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.71
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	35305000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	45829	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.39
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2844164	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.41
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	124585000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	703838	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	159.67
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	624315	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.29
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	54821000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	66123	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	44.57
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2857564	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.09
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	351626000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1210447	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.38
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2020	insp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable	200578000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11100000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5100000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	200000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12817000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6197000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1219000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	72700000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	70000	USD
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	45000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	85000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	40000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	40000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	115000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	40000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	115000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115381000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82050000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50593000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.040
CY2020	insp	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	0.080
CY2019	insp	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	0.039
CY2018	insp	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	0.014
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.014
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.010
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.341
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.297
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.263
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	58150000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39925000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31120000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3761000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2348000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1916000	USD
CY2020Q4	insp	Deferred Tax Assets Tax Deferred Expense Research And Development Expenditures Capitalized For Tax DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentExpendituresCapitalizedForTax	1846000	USD
CY2019Q4	insp	Deferred Tax Assets Tax Deferred Expense Research And Development Expenditures Capitalized For Tax DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentExpendituresCapitalizedForTax	3111000	USD
CY2018Q4	insp	Deferred Tax Assets Tax Deferred Expense Research And Development Expenditures Capitalized For Tax DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentExpendituresCapitalizedForTax	2549000	USD
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	252000	USD
CY2019Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0	USD
CY2018Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	638000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1330000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	221000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1194000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	167000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	311000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	1444000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	202000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1770000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	813000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	214000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	16000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68590000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47950000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37958000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2857564	shares
CY2020Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	1424000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	223000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	7000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	25000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5800000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	50000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	101000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1431000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	298000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	101000	USD
CY2020Q4	insp	Deferred Tax Assets Gross Net Of Deferred Tax Liabilities DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities	67159000	USD
CY2019Q4	insp	Deferred Tax Assets Gross Net Of Deferred Tax Liabilities DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities	47652000	USD
CY2018Q4	insp	Deferred Tax Assets Gross Net Of Deferred Tax Liabilities DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities	37857000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67159000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47652000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37857000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19500000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9800000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	40000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	40000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2844164	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2751751	shares
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20862000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21347000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12183000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35842000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46009000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16250000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18032000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26906000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	18050000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	10229000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	30631000	USD
CY2020Q4	us-gaap	Gross Profit GrossProfit	38848000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	13396000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	14938000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	17406000	USD
CY2019Q4	us-gaap	Gross Profit GrossProfit	22667000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16245000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-23089000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-10385000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-7484000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8266000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-7650000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-8247000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-9080000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38

Files In Submission

Name	View Source	Status
0001609550-21-000010-index-headers.html	Edgar Link	pending
0001609550-21-000010-index.html	Edgar Link	pending
0001609550-21-000010.txt	Edgar Link	pending
0001609550-21-000010-xbrl.zip	Edgar Link	pending
a202010kex21-1.htm	Edgar Link	pending
a202010kex23-1.htm	Edgar Link	pending
a202010kex31-1.htm	Edgar Link	pending
a202010kex31-2.htm	Edgar Link	pending
a202010kex32-1.htm	Edgar Link	pending
a202010kex32-2.htm	Edgar Link	pending
exhibit10-13rsuagreement.htm	Edgar Link	pending
exhibit10-13rsuagreement001.jpg	Edgar Link	pending
exhibit10-13rsuagreement002.jpg	Edgar Link	pending
exhibit10-13rsuagreement003.jpg	Edgar Link	pending
exhibit10-13rsuagreement004.jpg	Edgar Link	pending
exhibit10-13rsuagreement005.jpg	Edgar Link	pending
exhibit10-13rsuagreement006.jpg	Edgar Link	pending
exhibit1020bryanphillips.htm	Edgar Link	pending
exhibit1020bryanphillips001.jpg	Edgar Link	pending
exhibit1020bryanphillips002.jpg	Edgar Link	pending
exhibit1020bryanphillips003.jpg	Edgar Link	pending
exhibit1020bryanphillips004.jpg	Edgar Link	pending
exhibit1020bryanphillips005.jpg	Edgar Link	pending
exhibit1020bryanphillips006.jpg	Edgar Link	pending
exhibit1020bryanphillips007.jpg	Edgar Link	pending
exhibit1020bryanphillips008.jpg	Edgar Link	pending
exhibit1020bryanphillips009.jpg	Edgar Link	pending
exhibit1020bryanphillips010.jpg	Edgar Link	pending
exhibit1020bryanphillips011.jpg	Edgar Link	pending
exhibit1020bryanphillips012.jpg	Edgar Link	pending
exhibit1020bryanphillips013.jpg	Edgar Link	pending
exhibit1020bryanphillips014.jpg	Edgar Link	pending
exhibit1020bryanphillips015.jpg	Edgar Link	pending
exhibit1020bryanphillips016.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
insp-20201231.htm	Edgar Link	pending
insp-20201231.xsd	Edgar Link	pending
insp-20201231_cal.xml	Edgar Link	unprocessable
insp-20201231_def.xml	Edgar Link	unprocessable
insp-20201231_g1.jpg	Edgar Link	pending
insp-20201231_g10.jpg	Edgar Link	pending
insp-20201231_g11.jpg	Edgar Link	pending
insp-20201231_g12.jpg	Edgar Link	pending
insp-20201231_g13.jpg	Edgar Link	pending
insp-20201231_g14.jpg	Edgar Link	pending
insp-20201231_g15.jpg	Edgar Link	pending
insp-20201231_g16.jpg	Edgar Link	pending
insp-20201231_g17.jpg	Edgar Link	pending
insp-20201231_g18.jpg	Edgar Link	pending
insp-20201231_g19.jpg	Edgar Link	pending
insp-20201231_g2.jpg	Edgar Link	pending
insp-20201231_g20.jpg	Edgar Link	pending
insp-20201231_g21.jpg	Edgar Link	pending
insp-20201231_g22.jpg	Edgar Link	pending
insp-20201231_g23.jpg	Edgar Link	pending
insp-20201231_g24.jpg	Edgar Link	pending
insp-20201231_g25.jpg	Edgar Link	pending
insp-20201231_g26.jpg	Edgar Link	pending
insp-20201231_g27.jpg	Edgar Link	pending
insp-20201231_g3.jpg	Edgar Link	pending
insp-20201231_g4.jpg	Edgar Link	pending
insp-20201231_g5.jpg	Edgar Link	pending
insp-20201231_g6.jpg	Edgar Link	pending
insp-20201231_g7.jpg	Edgar Link	pending
insp-20201231_g8.jpg	Edgar Link	pending
insp-20201231_g9.jpg	Edgar Link	pending
insp-20201231_htm.xml	Edgar Link	completed
insp-20201231_lab.xml	Edgar Link	unprocessable
insp-20201231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSP
Inspire Medical Systems, Inc. Stock $insp

2020 Q4 Form 10-K Financial Statement

#000160955021000010 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP Inspire Medical Systems, Inc. Stock $insp

2020 Q4 Form 10-K Financial Statement

#000160955021000010 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP
Inspire Medical Systems, Inc. Stock $insp